The Kromite Team
Jack Kloeber is a retired US Army Lieutenant Colonel with experience in R&D portfolio management, decision analysis, modeling and simulation, technology selection, and strategy development. Jack taught mathematics at West Point for three years, and graduate level decision analysis, systems simulation, and technology selection for six years at the Air Force Institute of Technology. His work has supported decisions for various superfund sites within the Department of Energy, and many technology organizations within the Departments of Army, Air Force, and Navy. Jack was the head of Portfolio Management for Bristol-Myers Squibb, and more recently, head of Portfolio Management for J&J Pharma Services where he coordinated the portfolio management efforts across multiple R&D and marketing operating companies. Jack was a Senior Partner at KROMITE for 5 years and is now Principal.
He received his Ph.D. in Economic Decision Analysis from Georgia Institute of Technology and Masters in Industrial Engineering from Lehigh University.
Jack is a member and Fellow of the Society of Decision Professionals, a member of the Decisions Analysis Society, and a 25-year member of the Institute for Operations Research and the Management Sciences (INFORMS).
Phillip Beccue specializes in the application of decision analysis, financial modeling, portfolio optimization, and risk analysis to strategic business problems. For over twenty years, Phil has helped companies develop corporate and asset strategies and improve portfolio management and business operations. For the past seven years, his pioneering work in the development of tools and processes has directed top executives in allocating an annual R&D investment of $500 million at Baxter Healthcare. His leadership ensured a timely, disciplined, and consistent process to manage uncertainty across diverse businesses where it was necessary to balance near-term and long-term impacts of a dynamic business environment. He has trained over 700 managers and senior executives on the principles and processes of strategic decision-making. He is a frequent speaker in executive decision programs, won an industry award for real-world applications, serves as Associate Editor for the Decision Analysis Journal, and is a contributing author of Advances in Decision Analysis (Cambridge University Press, 2007).
Prior to joining Baxter, Phil was responsible for building the Decision Sciences group at Amgen and played a key role in institutionalizing decision analytic processes. Before joining Amgen he was a management consultant with Applied Decision Analysis, where he helped clients in diverse industries solve challenging business problems in strategy, prioritization, and risk analysis.
Phil received degrees from both Westmont College and Stanford University.
Phil is a Fellow of the Society of Decision Professionals and a long time member of the Decision Analysis Society.
Terry Bresnick is the former CEO, President, and co-founder of Innovative Decisions, Inc. in Vienna, VA, and is President of Innovative Decision Analysis. Previously, he was VP of Decision Science Consortium, and a Decision Analyst with Decisions and Designs, Inc, as well as Assistant Professor of Systems and Decision Analysis at the U.S. Military Academy. Terry has more than 38 years experience applying decision analysis to complex problems of government and industry and has facilitated more than 1000 decision conferences, workshops, and seminars.
First as an officer in the U.S. Army, and currently as a consultant in the private sector, he serves clients in the areas of decision analysis, risk analysis, strategic planning, resource allocation and budgetary analysis, evaluation of competing alternatives, and cost-benefit analysis.
Terry is a past recipient of the Rist Prize by the Military Operations Research Society (MORS), has had three Best Decision Analysis Working Group Papers at MORS, and has been runner-up in the INFORMS Decision Analysis Society annual Best Application competition. He is a co-author of the Handbook for Decision Analysis published in March 2013, and has published numerous articles in refereed journals as well as book chapters.
Terry holds the Degree of Engineer in Engineering-Economic Systems and an M.S. in Statistics, both from Stanford University; an M.B.A. in Decision Science from George Mason University; and a B.S. in Engineering from the U.S. Military Academy.
He is currently a Fellow and board member of the Society of Decision Professionals, a Certified Financial Planner, and a registered Professional Engineer in Virginia.
David has 20 years of experience in the pharmaceutical, nutritionals, and consumer products industries with a range of assignments in Commercial, Financial, Technical, and Analytical positions. His strengths are concentrated in sales forecasting, market analytics, finance, and modeling. Prior to joining KROMITE, David was responsible for search and evaluation of new business opportunities and developing strategic sales forecasts at Axcan, primarily in specialty Gastroenterology areas such as Crohn's Disease, Ulcerative Colitis, and Pancreatic Enzymes. He also created financial models to support business development projects. Prior to Axcan, David was a member of the forecasting and modeling team and Finance organizations at Johnson & Johnson for 3 years. There, he developed global market models and forecasts for multiple virology therapeutic indications with a specific focus in Hepatitis C. His Finance roles included supporting Sales, Marketing, R&D, and Business Development as a senior financial analyst.
David has outstanding analytical and modeling abilities, which he has honed throughout his career. He also has a strong financial background including having managed and refined the company capital requisition process at Mars.
David has a BS in Chemical Engineering and an MBA in Finance from Lehigh University.
Roger Holdsworth has over 20 years experience in senior management in the Biopharmaceutical industry. He was educated as a physiologist and started in R&D project management, moving on to alliance and portfolio management. Over this period, he has been involved in a broad range of development activities both from the R&D and commercial point of view.
For the past ten years he has held senior posts in portfolio management, beginning with the set up of the portfolio analysis and management system in the UK Biotechnology company, Celltech, in 2000. His role in portfolio management continued following the acquisition of Celltech by the Belgian Pharmaceutical company UCB in 2004. From that time until the end of 2010, he was Director of R&D Portfolio Management, latterly based in the Global Operations group. There he carried out the evaluation of a broad portfolio of chemical and biological entities in the CNS and Immunology therapeutic areas using financial and non-financial techniques including both net present value-based and risk and attribute analysis and provided decision support relating to late phase development to the most senior management groups within the company.
Before moving into portfolio management, he was a senior project leader in the Celltech organization where he was responsible for a number of major biologic development projects. In particular he led a number of important development alliances with large international pharmaceutical companies.
Roger heads up the KROMITE business development efforts in Europe.
Steve Hamlen has over 20 years of pharmaceutical and life sciences commercial assessment and marketing management experience including in-line Brand Management, Global Strategic Marketing, and Global Commercial Assessment roles. His experience includes identification and optimization of investments for life cycle strategies, creative in-line marketing campaigns, indication sequencing of internal pipeline investments and external licensing opportunities for Anemia/Pain/Oncology/Oncology Supportive Care/Nephrology/GI therapeutic areas to maximize business value.
In these roles, Steve has led and translated targeting, messaging, segmentation, positioning, market research, and probabilistic forecasting into actionable business plans and campaigns for numerous established and pipeline products, some of which were over $1 billion/year in sales at Johnson & Johnson. He has also launched two drug delivery technology platforms at Catalent Pharma Solutions designed to enhance product differentiation through application of controlled and targeted release.
Steve has a BS in Chemical Engineering and an MBA in marketing from Lehigh University, and has multiple publications on the topics of target product profile and patient adherence enhancement through controlled release technologies.
C. Kwon Kim,
Kwon Kim has twelve years of business experience in the biotechnology, pharmaceutical and medical device industries. Prior to joining KROMITE, he was Project Manager at Angiotech Pharmaceuticals where he managed clinical and regulatory stage projects focusing on proprietary drug-device combination products. At Baxter BioScience, he was a core member of the Strategy and Portfolio Management Group. He was responsible for the design and implementation of the portfolio prioritization process for a R&D budget of approximately quarter billion dollars. In addition, Kwon developed new guidelines for technical and commercial assessments, and asset valuations of all pipeline projects. At Strategic Decisions Group (SDG), he was a management consultant providing strategic decision support for life sciences companies. Kwon has experience in several therapeutic areas, including CNS, cardiovascular, endocrinology, pulmonology and hemophilia.
Prior to joining SDG, he was a research scientist at The Salk Institute. He holds a Ph.D. in Neurosciences, and M.A. and B.Sc. in Biopsychology from the University of British Columbia.
Kwon is a member of Decision Analysis Affinity Group and the Society of Decision Professionals.
Regina Klein brings extensive experience in knowledge management, competitive intelligence and strategic planning. Prior to KROMITE, she worked for Pharmacia, Monsanto, Washington University School of Medicine, Central Missouri State University, and Elsevier Clinical Medicine Journals.
She was responsible for technology intelligence and strategy development in the R&D Strategy organization at Pharmacia. At Monsanto, she created the business intelligence function supporting R&D, commercial development, alliances, and strategic decision making in the Nutrition & Consumer Sector. She was a member of the leadership team for the Monsanto Information Resources and Services group, with responsibility for strategy and planning for global business information development and delivery. Regina has written and lectured on the topics of competitive intelligence and knowledge management and their use in strategy development and portfolio management.
She received her B.A. and M.A. degrees in Library Science and Information Science from the University of Missouri. Her M.B.A. is from Southern Illinois University. She completed the Advanced Skills Training Program at the Centre for Operational Business Intelligence and the Academy of Competitive Intelligence at Georgetown University.
Scott Lamb brings over 22 years of progressive experience as a business leader in R&D, Portfolio & Program Management and Commercial roles for Procter & Gamble, Johnson & Johnson and Catalent. He has consistently delivered revenue and portfolio growth through innovation (products, technology, & processes), strategic planning, alliances, simplicity, capability enhancement (governance & workflow), and a unique ability to lead, translate and build relationships across technical and commercial groups. Prior to joining KROMITE, Scott was head of R&D for Catalent’s MRT (Oral Solids) unit with operational responsibility for $60 million annual R&D revenue, 110 employees across five global sites, and the BASF open alliance. In 2012, he left Johnson & Johnson after 14 years with J&J Consumer Products Worldwide, OTC Global Business Unit (McNeil), and Global Medical Device & Diagnostics R&D.
Scott’s knowledge spans Discovery to Commercialization and includes broad commercial, portfolio and scientific experience in pharmaceuticals, medical devices, and consumer products. He has contributed directly to numerous therapeutic areas and products, including: Oral (Rembrandt acquisition and re-launch), GI (Prilosec Rx-to-OTC), Intimate Health (K-Y Warming, Monistat 1-day ovule anytime dosing), Dermatology (Tretinoin, Aveeno, RoC, Neutrogena and Clean&Clear), Respiratory (Zyrtec Rx-to-OTC) and Analgesics (Aleve Rx-to-OTC and pill count demo., Tylenol Rapid Release Gels). He has also led design and implementation of enterprise governance and portfolio management capability and IT systems for three J&J units: JJCC Global R&D, Global OTC and ATRM.
Scott's educational background is in chemical engineering and economics from the University of Delaware and he holds four issued US patents.
Mark Lane has over 20 years of scientific and product development experience in the biopharmaceutical and medical device industries. His expertise includes Global New Product Development, Program Leadership, Project and Portfolio Management, In License Assessment and Governance.
He has led multiple cross-functional product development teams in crafting global development and lifecycle strategies for multiple assets at Merck, Wyeth, and Medimmune in several therapy areas including Diabetes, Obesity, Atherosclerosis, Arrhythmia, and Inflammatory Diseases. Mark has also led numerous in license assessments (Ph 0-4) in these therapy areas comprised of technical due diligence and development of the value proposition and commercialization strategies.
At GE Medical Diagnostics and LifeCell he led the Program Leadership and Project and Portfolio Management functions with accountability for leading development of project strategies to appropriately address unmet needs and ensure delivery of key strategic objectives and value to the business. Mark’s responsibilities also included managing the development project portfolios to maximize short- and long-term value and for driving effective decision-making and portfolio optimization through project governance.
Mark received his Masters and PhD in Physiology from Penn State University and prior to joining industry was a Fellow and Chief of the Nutritional and Molecular Physiology Unit at the National Institute on Aging with 110 scientific publications.
Stephen Mack is a decision management consultant with over 20 years of experience. He specializes in integrating both quantitative and qualitative decision support methodologies as part of a holistic decision management process. Steve is very experienced in strategy development and project portfolio management using group collaborative tools, prioritization and optimization methods, and project portfolio management systems. Clients he has supported include commercial organizations and U.S. government program offices with portfolio budgets that ranged up to 1 billion dollars in total value.
Steve’s quantitative skill set includes mathematical optimization, discrete event simulation, Monte Carlo risk modeling, statistical analysis and Visual Basic programming. He has developed end user models in Microsoft Excel, Access, Visio and ExtendSim. Steve is also a trained group facilitator, and is skilled with GroupSystems and Expert Choice decision support software, as well as with other group collaborative technologies.
Steve has an M.S. in Operations Research from The George Washington University and a B.S. in Chemistry from Drexel University. He has held corporate positions with FMC Corporation and American Airlines and consulting positions with Energetics, Inc. and Whitney, Bradley & Brown, Inc.
Brig Masone, with over ten years of marketing experience in the biotech industry, is KROMITE's senior marketing expert. During her time at the German biotech company QIAGEN, Brig was instrumental in establishing QIAGEN as the leader in RNA purification and expanding into RNA enzymes and stabilization. Her responsibilities included strategic marketing and forecasting for the entire RNA product portfolio worldwide as well as product management and training for North America.
Brig received her Master of Science degree in Molecular Genetics and Biochemistry from The University of Pittsburgh School of Medicine and her Bachelor of Science degree in Microbiology from The Pennsylvania State University.
In addition to coaching a Youth Track team, she captains an American Cancer Society Relay For Life team and is fluent in German.
Mary has over 15 years of experience in plant breeding including inbred development, hybrid creation, and plant pathology methods. She received her Master of Science and Ph.D. in agronomy and plant breeding under the prestigious guidance of pepper breeder Paul Bosland at New Mexico State University. Following her studies, Mary worked at a post-doctorate position breeding cayenne peppers and determining the speciation of the Capsicum genus.
Mary held the title of Project Leader for the hybrid pepper program at Sakata Seed America, Inc. for over 10 years. She was responsible for the creation and development of inbred lines and families as well as the formation of new hybrids and their commercialization. More than a dozen of these hybrids are currently in use by commercial growers and include seven types of peppers. She also collaborated globally with the corporation’s breeders in France, Korea, and Brazil.
Mary is also pursuing a degree in business from Florida Gulf Coast University.
Mary brings 5 years of experience in management, as Branch Office Manager for a national legal support company, and eventually as the company’s Manager of Contractor Relations for the Mid-West region. In addition, she has worked over 6 years in the administrative field, with an emphasis on legal support. Her work has consisted of team operations, recruiting, training efforts, court relations, quality control, contract negotiations, conflict resolution, and legal compliance - all with a focus on customer service and confidentiality.
Mary is a Notary Public in the State of Ohio, and currently manages KROMITE’s Operations, Accounting and Payroll.